NCT06115642
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06115642
Title A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
Recruitment Enrolling by invitation
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Shanghai Henlius Biotech
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Stanford University Stanford California 94305 United States Details
Georgetown University Washington D.C. District of Columbia 20057 United States Details
MD Anderson Medical Center Houston Texas 77030 United States Details
Cancer Hospital, Chinese Academy of Medical Sciences Beijing Beijing Municipality China Details
Xiangya Hospital Central South University Changsha Hu'nan 410008 China Details
Sendai Kousei Hospital Sendai Miyagi 980-0873 Japan Details
Kindai University Hospital Sayama Osaka 589-8511 Japan Details
Okayama University Hospital Okayama 700-8558 Japan Details
Shizuoka Cancer Center Shizuoka 411-8777 Japan Details
National Cancer Center Hospital Tokyo 104-0045 Japan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field